Sec Form 3 Filing - Schultes Birgit C @ Intellia Therapeutics, Inc. - 2025-01-13

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Schultes Birgit C 2. Issuer Name and Ticker or Trading Symbol Intellia Therapeutics, Inc. [ NTLA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) EVP, Chief Scientific Officer (Last) (First) (Middle) C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130 3. Date of Earliest Transaction (MM/DD/YY) 01/13/2025 (Street) CAMBRIDGE, MA02139 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 67,615 ( 1 ) D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (right to buy) $ 27.33 ( 2 ) 10/01/2027 Common Stock 40,000 < span class="form4-data"> D Stock Option (right to buy) $ 18.3 ( 3 ) 12/11/2027 Common Stock 20,000 D Stock Option (right to buy) $ 14.58 ( 4 ) 12/17/2028 Common Stock 10,625 D Stock Option (right to buy) $ 13.4 ( 5 ) 03/01/2030 Common Stock 30,000 D Stock Option (right to buy) $ 57.71 ( 6 ) 03/02/2031 Common Stock 20,600 D Stock Option (right to buy) $ 134.06 ( 7 ) 09/30/2031 Common Stock 3,500 D Stock Option (right to buy) $ 40.75 ( 8 ) 02/28/2033 Common Stock 24,965 D Stock Option (right to buy) $ 32.66 ( 9 ) 02/28/2034 Common Stock 31,816 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Schultes Birgit C C/O INTELLIA THERAPEUTICS, INC. 40 ERIE STREET, SUITE 130 CAMBRIDGE, MA02139 EVP, Chief Scientific Officer Signatures James Basta, attorney-in-fact 01/23/2025 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Includes (i) a grant of 16,080 restricted stock units, (ii) a grant of 7,500 restricted stock units, (iii) a grant of 3,440 restricted stock units, (iiii) a grant of 400 restricted stock units, (v) a grant of 20,839 restricted stock units, (vi) a grant of 17,668 restricted stock units, and (vii) a grant of 22,045 restricted stock units, each representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. ( 2 )This option was granted on October 2, 2017 with respect to 40,000 shares of Common Stock, with 25% vesting on September 18, 2018 and the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter. ( 3 )This option was granted on December 12, 2017 with respect to 20,000 shares of Common Stock, with 25% vesting on December 12, 2018 and the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter. ( 4 )This option was granted on December 18, 2018 with respect to 30,000 shares of Common Stock, with 25% vesting on December 18, 2019 and the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter. ( 5 )This option was granted on March 2, 2020 with respect to 30,000 shares of Common Stock, with 25% vesting on January 1, 2021 and the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter. ( 6 )This option was granted on March 3, 2021 with respect to 20,600 shares of Common Stock, with 25% vesting on January 1, 2022 and the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter. ( 7 )This option was granted on October 1, 2021 with respect to 3,500 shares of Common Stock, with 25% vesting on October 1, 2022 and the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter. ( 8 )This option was granted on March 1, 2023 with respect to 24,965 shares of Common Stock, with 33% vesting on January 1, 2024 and the remaining 67% vesting in twenty-four (24) substantially equal monthly installments thereafter. ( 9 )This option was granted on March 1, 2024 with respect to 31,816 shares of Common Stock, with 33% vesting on January 1, 2025 and the remaining 67% vesting in twenty-four (24) substantially equal monthly installments thereafter.

Remarks: Exhibit 24.1 - Power of Attorney.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.